Loading
A phase 2 trial of Olaparib, Durvalumab in ovarian cancer, run by AGO Research GmbH, now recruiting.
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC is a phase 2 interventional study registered as NCT04644289 by AGO Research GmbH, with 60 participants planned, started 2022-05-05 and due to reach its primary completion in 2028-01. Interventions recorded: olaparib, durvalumab. Conditions listed: Epithelial Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares PARP inhibitors, Olaparib, Durvalumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Durvalumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares PARP inhibitors, Olaparib, Durvalumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Shares PARP inhibitors, Olaparib, Durvalumab, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Immune checkpoint inhibitors.
Shares PARP inhibitors, Olaparib, Immune checkpoint inhibitors.